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Abstract  
Background 
Pruritic skin rashes associated with exposure to freshwater cyanobacteria are infrequently 
reported in the medical and scientific literature, mostly as anecdotal and case reports. 
Diagnostic dermatological investigations in humans are also infrequently described. We 
sought to conduct a pilot volunteer study to explore the potential for cyanobacteria to 
elicit hypersensitivity reactions. 
Methods 
A consecutive series of adult patients presenting for diagnostic skin patch testing at a 
hospital outpatient clinic were invited to participate. A convenience sample of volunteers 
matched for age and sex were also enrolled. Patches containing aqueous suspensions of 
various cyanobacteria at three concentrations were applied for 48 hours; dermatological 
assessment was made 48 hours and 96 hours after application.  
Results 
20 outpatients and 19 reference subjects were recruited into the study. A single outpatient 
produced unequivocal reactions to several cyanobacteria suspensions; this subject was 
also the only one of the outpatient group with a diagnosis of atopic dermatitis. No 
subjects in the reference group developed clinically detectable skin reactions to 
cyanobacteria. 
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Conclusions 
This preliminary clinical study demonstrates that hypersensitivity reactions to 
cyanobacteria appear to be infrequent in both the general and dermatological outpatient 
populations. As cyanobacteria are widely distributed in aquatic environments, a better 
appreciation of risk factors, particularly with respect to allergic predisposition, may help 
to refine health advice given to people engaging in recreational activities where nuisance 
cyanobacteria are a problem.  
 
 
Background  
 
Cyanobacteria, commonly but erroneously known as blue-green algae, are common 
inhabitants of freshwater lakes and reservoirs throughout the world. Under favourable 
conditions certain cyanobacteria can dominate the phytoplankton within a waterbody and 
undergo mass developments, known as blooms. Public health concerns arise because 
many nuisance cyanobacteria can produce potent toxins. Anecdotal and case reports have 
documented skin rashes, often described as intensely pruritic, associated with contact 
exposure to cyanobacteria. While there are relatively few references in the scientific and 
medical literature since these reports began in 1949, under-diagnosis of cyanobacteria-
associated illness was suggested by Schwimmer & Schwimmer [1] in 1968, a suspicion 
that probably holds today. Most reports of cyanobacteria-associated skin eruptions 
describe recreational or occupational exposure [2], however there are anecdotal reports of 
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skin rashes related to water treatment failures and subsequent presence of cyanobacterial 
products in reticulated supplies. In these instances, skin rashes were reported after 
showering or bathing [3, 4]. “Several” people experienced acute dermatitis, as well as 
gastrointestinal symptoms, after drinking water from a riverine source affected by a 
cyanobacteria bloom in Portugal [5]. 
 
Skin patch testing is a routine diagnostic procedure in dermatology clinics worldwide, 
and testing with cyanobacterial preparations was first reported in the USA in 1953 to 
investigate a water contact-related seasonal dermatitis in a girl aged six years. Strong 
positive reactions to various extracts of an Anabaena sp. dominant bloom sample were 
observed on the child but none of 25 healthy control subjects [6].  
 
In a study of volunteers to investigate irritant reactions, Pilotto et al [7] reported that 20-
24% of subjects reacted to cyanobacterial test patches, and 23% of subjects responded to 
negative control patches. After excluding subjects who responded to the negative 
controls, 11-15% of subjects responded to cyanobacteria. No dose-response relationships 
were reported.  
 
Intracutaneous testing of cyanobacteria to investigate cases of respiratory allergy has a 
long history, with convincing and sometimes dramatic immediate-type reactions seen on 
the skin of susceptible individuals, and negative responses from (presumably) healthy 
individuals [8, 9].  
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 Anecdotal and case reports in the medical and scientific literature do not provide 
convincing descriptions of mass outbreaks of cutaneous symptoms associated with 
recreational or occupational exposure to planktonic cyanobacteria. Rather, the picture is 
of isolated events affecting individuals or small numbers of people [2]. An 
epidemiological study to investigate the occurrence of acute symptoms did not find a 
statistically significant difference in the reporting of cutaneous symptoms across groups 
exposed to different levels of planktonic cyanobacteria in recreational waters. The small 
number of subjects that reported skin ailments after bathing in cyanobacteria-affected 
waters mostly rated the severity of symptoms as mild [10]. Taken together, these findings 
suggest that nuisance planktonic cyanobacteria are not commonly present at irritant 
concentrations in inland recreational waters, unlike the marine filamentous 
cyanobacterium Lyngbya majuscula, which is known to produce dermally-active toxins 
and has been linked to mass outbreaks of acute dermatitis involving hundreds of 
individuals, with high proportions of exposed individuals being affected [11].  
 
The purpose of this study was to assess the propensity for a range of cyanobacterial 
suspensions to induce cutaneous irritant and hypersensitivity reactions in dermatology 
outpatients and a reference group of volunteers matched for age and sex. We wished to 
determine whether threshold doses that induce reactions in the reference group, if indeed 
such reactions occur in this group, are lower in individuals with an active history of 
cutaneous symptoms. Irritant and hypersensitivity reactions would be determined both 
qualitatively and quantitatively, and the cyanobacteria would be characterised in terms of 
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species (or genera if speciation were not possible), doses to be applied to the skin, and the 
presence or absence of known toxins.  
 
 
Methods 
 
Study participants, patch application and reading 
 
A consecutive series of adults aged 18 to 65 years presenting for diagnostic skin patch 
testing at the Royal Brisbane and Women’s Hospital dermatology outpatient clinic 
between March 2002 and November 2003 was invited to participate in the study – 
provided they met study inclusion criteria – until 20 were recruited. A convenience 
sample of volunteers was recruited via notices posted at three university sites and by 
word of mouth for the reference group. Patients and reference subjects were matched by 
sex and, where possible, by age using 5 year age bands. Routine exclusion criteria for 
elective patch testing applied to this study: persons with infectious dermatoses, 
widespread acne, traumatic lesion or excess hair on their back. Pregnant women were also 
excluded.  
 
Study subjects were asked to complete a simple questionnaire that requested basic 
demographic details (age, sex), history of allergic illness (asthma, hay fever, eczema, 
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urticaria), relevant medications and a description of any freshwater-related dermatoses 
[12 (Appendix 4)].  
 
The skin patch testing procedure uses a series of shallow aluminium chambers (Finn 
chambers), 8mm internal diameter, 0.5mm depth, into which test materials are placed, 
either impregnated onto discs of filter paper or mixed in petrolatum [13]. Test material is 
placed in each chamber, and the Finn chamber strips are fixed on the skin with non 
occlusive, non-allergenic and non-irritant adhesive tape. For this study a clinic nurse 
prepared the skin of each subject’s back with acetone, and patches were applied to the 
skin. Study subjects were instructed to keep their back dry, i.e. bathe but not shower, and 
to refrain from sport or vigorous activity that might lead to frank perspiration, with 
resultant separation of Finn chamber strips from the skin. Patches were then removed 
after 48 hours. The clinic nurse marked the position of each Finn chamber with a 
permanent marker pen; after allowing adhesive tape-related erythema to subside, patch 
test sites were read by a dermatologist after 48 and approximately 96 hours. Patch sites 
were scored according to the key in Table 1. 
 
Dermatology clinic workers were blinded to the identity of test materials (patch series 
columns) but not to test concentrations (patch series rows) because we thought that 
identification of concentration-dependent (i.e. dose-response) reactions to any particular 
test suspension series would assist in the differentiation of irritant and hypersensitivity 
responses. Clinic workers were not blinded to the status of study subjects as either 
patients or non-patients.  
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 Ethical approvals for this study and amendments were granted by the Royal Brisbane 
Hospital Health Service District’s Human Research Ethics Committee, protocol number 
2001/151, and the University of Queensland’s Medical Research Ethics Committee, 
clearance number 2002000099. 
 
 
Patch test materials 
 
Six cyanobacterial suspensions, two cyanobacterial lipopolysaccharide extracts and one 
eukaryotic algal suspension were tested, each at three concentrations. Sodium dodecyl 
sulfate was used as a positive irritant control. The test materials and measured cyanotoxin 
concentrations are listed in Table 2. 
 
 
Culturing of cyanobacterial isolates; preparation of stock suspensions 
 
Cyanobacteria isolates were non-axenic laboratory cultures grown in sterile inorganic 
media in an illuminated growth chamber at 280C with a 14:10 light/dark cycle. Culture 
vessels were aerated with aquarium pumps and air-stones connected by PVC tubing; air 
was delivered through 0.45µm Millipore® filters, and all culture vessels and air delivery 
components distal to the filter (tubing, weights and air-stones) were sterilised prior to use 
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by steam autoclaving or Sterrad® hydrogen peroxide plasma sterilisation (the latter for 
heat labile plastics).   
 
M. aeruginosa and Planktothrix sp. cultures were grown in 20L batch cultures; M. 
aeruginosa cells were harvested by placing the culture vessel in a darkened cupboard 
overnight. This caused cells to rise to the surface of the vessel where they were aspirated 
with a syringe and PVC tubing. Planktothrix sp. is a filamentous cyanobacterium, so was 
easily harvested by plucking it in several continuous sheets from the vessel walls and 
aeration tubing. C. raciborskii was produced by a continuous culture method adapted 
from the method of Court et al [14] and cells were concentrated by centrifugation in 
750mL centrifuge bottles, then decanting and discarding media. Cells were double-
washed by repeat suspension in de-ionised water followed by centrifugation. 250mL of C. 
vulgaris culture was purchased from CSIRO Hobart, which after double washing yielded 
sufficient cellular material for this work. Harvested cells were lyophilised, powdered with 
a domestic coffee grinder and stored at room temperature in air-tight containers. 
  
Stock preparations were made by suspending 25mg lyophilised cells in 10mL Milli-Q® 
filtered water to produce 0.25%w/v suspensions. These were steeped overnight at 4P0C. 
Cell integrity was disrupted by subjecting each suspension to ultrasonic pulsing for 30 
seconds, using a Branson Ultrasonics Sonifier 450 instrument. 1mL of each 0.25% 
preparation was added to 4mL Milli-QP® water to produce the 0.05% suspension, and 
0.5mL of that preparation was added to 4.5mL water for the 0.005% suspension. All 
suspensions were stored at -20P0C. 
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Lipopolysaccharide (LPS) solutions were prepared from LPS isolated and purified  with a 
hot phenol method and ultracentrifugation, per procedures No. 4: Bacterial 
lipopolysaccharides – Gram-negative (modified Westphal) and No. 27: Purification of 
lipopolysaccharide (modified Westphal) [15 (pp.3-4, 31-2)], from the process described 
by Westphal & Jann [16]. LPS concentrations were based on the percentage yield from 
cyanobacterial whole cells they were extracted from: 
 
• M. aeruginosa LPS was 0.51% of dry cell weight, so the maximum concentration of 
LPS for skin patch testing was (5.1x10-3) x 0.25% w/v, i.e. 13ppm. Intermediate and 
low concentrations were prepared by diluting the 13ppm concentration as described 
above to give 3ppm and 300ppb concentrations. 
• C. raciborskii LPS was 1.25% of dry cell weight, so the three concentrations of 
 this LPS were 30ppm, 6ppm and 600ppb. 
  
Sodium dodecyl sulfate was prepared at concentrations of 2.0%, 0.4% and 0.04% (w/v in 
Milli-Q® water) and stored at -200C.  
 
Microcystins, saxitoxins and cylindrospermopsin were quantified at Queensland Health 
Scientific Services, Brisbane. These data are included in Table 2; methodology and 
instrumentation were as outlined in the accompanying paper by Stewart  et al [17]. 
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Cell biomass estimates 
 
Biomass estimates of lyophilised cyanobacteria were calculated from C. raciborskii AWT 
205 cultures grown as described above. Prior to harvesting cells from a 20L culture 
vessel, a 1L sample of the culture was lyophilised, and a culture sample was fixed in 
Lugol’s iodine for counting under phase contrast microscopy. The cell count of this C. 
raciborskii culture was determined, from which biovolume and surface area estimates 
were made. A Sedgwick-Rafter volumetric counting chamber was used; trichomes were 
counted in ten fields, and cells per trichome were counted in ten trichomes per field.  
 
 
Calculation of cyanotoxin doses applied to skin 
 
Cyanobacterial cell suspensions were applied to filter paper discs that fit into each Finn 
chamber. A plastic transfer pipette was used to saturate each disc; one or two drops – 
mostly one drop – are sufficient to saturate the disc. The volume of two transfer pipette 
drops was measured with an air displacement pipette and found to be 65μL. Doses were 
calculated from the maximum concentration (0.25%w/v), then one fifth and one fiftieth of 
the maximum dose, representing the 0.05%w/v and 0.005%w/v concentrations, were 
added to estimate the total cutaneous dose for an average 65kg subject.  
 
 
Statistical analysis 
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 Comparisons of categorical variables were undertaken using Fisher’s exact test. A p-
value <0.05 was used to define statistical significance and all calculations were conducted 
using SPSS v13.0. Investigation into the incidence of reactions and threshold 
concentrations of cyanobacteria, adjusted for covariates including reported history of 
asthma, urticaria or hay fever was planned but not done because only a single subject 
developed unequivocal reactions to patches containing cyanobacteria.  
 
 
RESULTS 
 
From the consecutive series of outpatients approached, two declined to participate (one of 
each sex) and one female who agreed to participate was not included due to an 
administrative oversight. All outpatients were matched to reference subjects by sex 
(females: n=12; males: n=8). Matching was also done by age (± 5 years), except for three 
older outpatient subjects (aged 54, 56 and 62 years).  
 
Responses to the questionnaire enquiry regarding a previous history of allergic illness and 
acute or chronic skin reactions are summarised in Table 3. Outpatients reported 
significantly more life-time and recent eczema or dermatitis diagnoses (p=0.04 and 
p=0.01 respectively), and rash of unknown cause within the last two years (p=0.003) than 
their reference counterparts.  
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Skin patch testing – cyanobacterial and algal suspensions 
 
Subjects CO10 and PT05 were removed from consideration of summary statistics given 
in Table 2. Subject CO10 developed a localised folliculitis over four test series sites – one 
being the SDS series – so 96-hour readings were uninterpretable. The dermatologist noted 
a general irritant reaction over the patch area. We were unable to recruit another volunteer 
in her place, thus the study included 19 reference subjects. Subject PT05 developed 
“angry back”, which is a state of skin hyper-reactivity caused by a strong reaction to one 
or more patch-test allergens, and is associated with false-positive reactions to other test 
materials [18 (pp.16-17)]; another outpatient subject was recruited to replace this subject 
in the study. 
 
Table 4 shows results of patch test inspections of the cyanobacterial and algal series. Only 
one of the outpatient group and none of the reference group showed an unequivocal 
reaction to cyanobacterial preparations. A weak irritant response to an A. circinalis patch 
was seen in another dermatology outpatient subject, and equivocal responses to various 
patch materials were seen in four patients and four reference subjects. 
 
Estimated cyanotoxin doses applied to each subject are presented in Table 5. Assuming 
that two drops of cell suspension were required to saturate each Finn chamber filter disc, 
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and also assuming that the entire volume applied to the discs was in contact with subjects’ 
skin, all doses were well below the mammalian i.p. toxic dose.  
 
 
DISCUSSION 
 
Patch-testing of cyanobacteria and C. vulgaris 
 
Only one clear response to this skin-patch testing study was seen, from PT19, a male 
outpatient subject aged 35 years. Interestingly, this subject was also the only one of 20 
outpatients with a diagnosis of atopic dermatitis. We did not conduct any statistical 
analysis of these results, as it is not appropriate to make such comparisons on the basis of 
a single subject response. This subject developed unequivocal responses to two 
cyanobacterial isolates, two bloom samples, and probably to C. vulgaris as well. There 
was no evidence of any dose-response effect in the reactions on this subject’s skin. 
Another point of interest in this subject’s patch-test results is that reactions developed to 
the non-toxic Lake Coolmunda M. aeruginosa bloom sample, but no reaction was 
produced by the toxin-producing M. aeruginosa isolate. While the Coolmunda bloom 
sample was largely a monoculture of M. aeruginosa, as with many cyanobacteria blooms 
there were other cyanobacterial species and genera present in smaller amounts. This 
leaves open the possibility that this subject has demonstrated hypersensitivity reactions to 
components other than M. aeruginosa in the two bloom samples. Subject PT19 also 
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registered positive responses to both patch series containing C. raciborskii and 
cylindrospermopsin (C. raciborskii AWT 205 isolate and North Pine Dam bloom 
sample). This is interesting in light of the findings by Stewart et al [17], which 
demonstrate that C. raciborskii and purified cylindrospermopsin are capable of producing 
irritant and delayed-contact hypersensitivity in mice.  
 
The principal conclusions from this study are that cutaneous responses to cyanobacteria 
are uncommon, with only one of 39 subjects demonstrating significant cutaneous 
responses to cyanobacterial suspensions. Given this patient’s diagnosis of atopic 
dermatitis, and reports in the literature which are suggestive of other features of atopy [2], 
further research into this matter may benefit from more specific entry criteria to allow 
investigation of atopic individuals. This sole diagnosis of atopy must be interpreted 
cautiously, however, in that diagnoses were only available for the twenty outpatients. As 
the reference group did not have a comprehensive medical history taken, we cannot infer 
presence or absence of atopic subjects within the reference group.  
 
Weak reactions to C. vulgaris were seen on the skin of subject PT19, and possibly one 
other subject (PT04). C. vulgaris, a common and widespread eukaryotic alga, was chosen 
as a reference material; Chlorella spp. are reportedly allergenic [19, 20], although C. 
vulgaris has been promoted as an allergy preventative and has some anti-inflammatory 
properties [21]. Acute skin symptoms have been reported from exposure to other 
freshwater and marine eukaryotic microalgae [22, 23].   
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 Considering the single subject response to cyanobacterial patch testing, these data were 
used to determine sample size estimates that would produce a statistically significant 
result. Using nQuery Advisor 4.0 [24], a Fisher's exact test with a 0.050 two-sided 
significance level will have 80% power to detect the difference between a Group 1 
proportion of 0.050 and a Group 2 proportion of 0.001 when the sample size in each 
group is 167. A study involving over 300 volunteers would be prohibitively large and 
expensive; a more targeted approach in future to recruit subjects from more at-risk 
populations awaits further knowledge of the mechanisms of cyanobacterial toxicity by the 
cutaneous route. 
 
 
History of skin disease, allergy 
 
As anticipated, the outpatient group contained a higher proportion of subjects with 
cutaneous disease than the reference group (see Table 3). However, the percentage of 
subjects reporting hay-fever, asthma and urticarial diagnoses was higher in the reference 
group, although these differences were not statistically significant. To the extent that 
future research efforts in this field may need to concentrate on those individuals with 
atopic illness, recruitment from a dermatology outpatient population may not confer any 
particular advantage over recruitment from the general population.  
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 Reactions to sodium dodecyl sulfate 
 
44% of subjects (n=17) did not respond to SDS. Some workers have added SDS to their 
standard allergy patch test series in order to help differentiate between irritant and allergic 
reactions [25, 26]. (Irritant reactions are viewed as false-positive reactions in skin-patch 
testing for sensitising materials [18 (p.24)]. An irritant reaction is generally uniform, with 
a clear border; an allergic response is typically non-uniform, with an irregular border that 
may be seen beyond the patch site [27 (p.38)]). However, these workers did not appear to 
have blinded themselves to the location of SDS patches; they were apparently using 
reactions to SDS as reference irritant responses from which to compare reactions to 
allergen patches. We suspect that the inclusion of SDS as a positive irritant control may 
not have been the most appropriate procedure in this diagnostic patch testing study; this 
matter is discussed further by Stewart [12 (Chapter 4)].  
 
 
Cyanotoxin doses by the cutaneous route 
 
As seen in Table 5, estimated doses are well below any conceivably hazardous 
concentration in terms of systemic absorption. The doses applied to volunteer skin are 
more than four orders of magnitude lower than LD50 doses administered by the much 
more direct i.p. route. Another useful comparison that suggests the cutaneous doses 
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applied to our subjects were not acutely hazardous comes from guideline values for the 
acceptable daily intake of cyanotoxins by the oral route. Guideline values for 
microcystins in drinking water have been set at 1.3µg/L [28 (pp.238-42)], and a safety 
guideline of 1µg/L for cylindrospermopsin in drinking water has recently been 
recommended [29]. A concentration of 80µg saxitoxin equivalents per 100g shellfish is 
used in North America as a trigger for the closure of shellfish harvesting [30].  
 
 
Rationale for determining cyanobacteria concentrations in patch test wells 
 
Our initial challenge was to determine appropriate doses of cyanobacteria to apply to 
human skin. Prior to commencing this human volunteer study, preliminary irritant mouse 
ear swelling work had been done with two cyanobacterial suspensions at 5%w/v and 
10%w/v (lyophilised cyanobacteria in 75% methanol), with negative results [17]. 
Rietschel & Fowler [18 (p.15)] nominate appropriate steps for testing non-standard 
contactants: initial test concentrations of 0.1% to 1.0% performed on several volunteers, 
including the investigator. An autoexperiment was conducted on author IS in May 2001. 
Eight Finn chambers containing 5%w/v suspensions of M. aeruginosa QH/NR/Ma03 and 
a non-toxic bloom sample (Gordonbrook Dam, Queensland) containing predominantly A. 
circinalis were prepared; each suspension was applied with three vehicles: Milli-Q® 
water, 50%v/v methanol in Milli-Q® water, and acetone. Lyophilised, powdered M. 
aeruginosa and A. circinalis cells were each mixed in petrolatum and placed into two of 
the Finn chambers. Mild irritant reactions were seen on the aqueous A. circinalis 
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suspension site, and on the two petrolatum sites. Because author IS has never suffered 
from dermatitis, we suspected that the irritant reaction, albeit mild, was probably the 
result of an artificially high concentration of cyanobacterial cells. One of the problems of 
working with lyophilised cyanobacteria is relating the re-wetted concentration back to the 
biomass of cells when they were originally harvested. Cyanobacteria can achieve very 
high concentrations in bloom conditions, with densities of up to 3x109 cells/mL in what 
are described as hyperscums [31]. Cell counts of this magnitude equate to cell surface 
area estimates of >200,000mm2/mL, using the methods described by Stewart et al [10]. 
Cutaneous exposure to bloom-scale cell densities undoubtedly occurs in recreational and 
occupational settings, but the more common exposures would be to biomass 
concentrations several orders of magnitude lower than those reported by Zohary & 
Madeira [31]. The highest cyanobacterial biomass seen in recreational waters in an 
epidemiology study conducted by Stewart et al [10] was estimated at 318mm2/mL. From 
the results of Stewart [12 (Appendix 5)], biomass estimates for the 0.25%w/v maximum 
concentration suspensions used in this study would therefore be in the cell surface area 
>1,000mm2/mL range. A possibly more meaningful assessment of the doses applied to 
the skin of volunteers is that 0.25%w/v is a 20-fold lower concentration of cyanobacteria 
than that which elicited a mild irritant reaction on the skin of author IS during pre-testing 
experiments. 0.25%w/v is also a 20-40 fold lower concentration than those which failed 
to elicit observable or measurable reactions on mouse ears during open application 
experiments for irritancy [17].  
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We did not proceed with using powdered, lyophilised cyanobacteria mixed in petrolatum 
because of the anticipated loss of precision in determining doses. It was elected to use 
aqueous cyanobacterial suspensions for these patch testing studies, as water is the solvent 
of choice in the vast majority of recreational settings, from which arise reports of acute 
cyanobacteria-related dermatoses. Concomitant exposure to ethanol can often be 
observed in Australian recreational environments, but not by the cutaneous route. 
 
 
General discussion 
 
The findings of this small human study are that cutaneous reactions to cyanobacteria are 
infrequent, at least in the populations we sampled. The work in the accompanying paper 
by Stewart et al [17] complements this study, and demonstrates that purified 
cylindrospermopsin is capable of eliciting irritant and delayed-contact hypersensitivity 
reactions in mice. The small number of case and anecdotal reports in the literature also 
shows that cyanobacteria-associated dermatoses are infrequently reported, although mild, 
self-limiting illnesses, including pruritic rashes, are likely to be under-reported and under-
diagnosed [2, 32 (p.69)]. However, anecdotal reports of incident-free exposures to high 
levels of cyanobacteria have also been received [12 (Chapter 4)]; author IS has tried 
without success to generate a cutaneous response on his own skin through open 
application of concentrated cyanobacterial cells on many occasions, from both field 
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samples and laboratory isolates. Images of field workers demonstrating similarly 
enthusiastic disregard for occupational health and safety matters can be seen at: 
  
http://www-cyanosite.bio.purdue.edu/images/lgimages/collec.jpg
http://www-cyanosite.bio.purdue.edu/images/lgimages/microcy5.jpg
and 
http://www-cyanosite.bio.purdue.edu/images/lgimages/bloom11.jpg
 
The commercial sector has not been slow to realise that cutaneous responses to 
cyanobacteria are not unequivocally hazardous. A Google search using the terms “blue 
green algae” “soothes” and “skin” reveals a bewildering array of products and services 
that promise relief from much of what ails you. Many of these products are made from 
Arthrospira sp., a cyanobacterium also known as spirulina. Clinical and research 
dermatologists will no doubt be pleased to hear about: 
Spirulina Wrap 
Rich in antioxidant vitamins, spirulina is the ultimate nutrient boost. This 
treatment stimulates and nourishes the skin while promoting a healthy, more 
vibrant appereance (sic). (50 minutes) 
http://www.arizonabiltmore.com/spa/treatments.asp?ListMode=Menu&TID=151
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So there is still a great deal to learn about cyanobacteria and the skin. To what degree 
these widespread organisms may affect the health of individuals with atopic and non-
atopic allergic disease is unknown, but deserves the attention of researchers. The subject 
of photoallergy and photoirritancy has not been investigated. Most environmental 
exposures to aquatic cyanobacteria occur in recreational settings, which correlate strongly 
with exposure to sunlight, so photic effects should presumably be investigated.  
 
Whether cyanobacteria-associated cutaneous eruptions in susceptible individuals are 
primarily irritant reactions, immediate hypersensitivity or delayed contact 
hypersensitivity responses is not at all clear. The picture may turn out to be complex and 
varied, with similarities to the broad topic of phytodermatitis. Wilkinson and Shaw [33] 
list the principal presenting features of phytodermatitis thus: 
 
1. irritant contact phytodermatitis - both chemical and physical 
2. allergic contact phytodermatitis -  both immediate and delayed 
3. phytophototoxic dermatitis 
4. pseudophytophotodermatitis… 
5. allergic contact phytodermatitis with secondary photosensitivity… 
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Cyanobacteria-related dermatoses may also operate through different molecular 
mechanisms and may therefore vary in clinical presentation. Some sources of variability 
in the equation may be: 
 
• Individual susceptibility, e.g. atopic phenotype 
• Cyanobacteria profile in waterbodies – different species, genera, cell biomass 
• Cyanotoxins – different types, different mechanisms of toxicity, and variable 
 concentration in waterbodies (i.e. exposure and dose concerns) 
• Disruption to barrier function from waterlogged skin 
• Influence of ultra-violet irradiation – phototoxic effects or immunosuppressive? 
 
 
Conclusions 
 
This pilot study of 39 volunteers identified a single individual with atopic disease who 
responded to several cyanobacterial preparations applied to the skin by closed patch 
testing. Dose-response relationships were not observed in this individual, which supports 
the clinical findings that these were hypersensitivity reactions. This subject developed 
positive responses to all patch sites containing cylindrospermopsin, whereas none of the 
remaining 38 subjects showed any response to cylindrospermopsin. This work 
complements a mouse model study of delayed-contact hypersensitivity that demonstrates 
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cylindrospermopsin is active in mammalian epidermal tissues. Future work into 
cutaneous effects of cyanobacteria in humans may benefit from improved awareness of 
cellular and molecular mechanisms to allow more refined targeting of higher-risk 
populations.  
 
As case reports and epidemiologic studies do not present convincing findings of mass 
outbreaks of acute cutaneous responses to planktonic freshwater cyanobacteria, the 
possibility that many such reports are due to hypersensitivity reactions should be 
considered; these preliminary studies would seem to support this concept.   
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CSIRO  Commonwealth Scientific and Industrial Research Organisation 
 
i.p.   intraperitoneal 
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NPD   North Pine Dam 
 
ppb   parts per billion (μg/L) 
 
ppm   parts per million (mg/L) 
 
PVC   polyvinyl chloride 
 
SDS   sodium dodecyl sulfate (aka sodium lauryl sulfate) 
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Tables 
 
Table 1. Patch testing interpretation key 
 
+/- Uncertain reaction: faint macular erythema only 
+ Weak (nonvesicular) positive reaction; erythema, infiltration, possibly papules 
++ Strong (vesicular) positive reaction; erythema, infiltration, papules, vesicles 
+++ Extreme positive reaction; bullous reaction 
– Negative reaction 
IR Irritant reaction of different types 
Adapted from Rietschel & Fowler [18 (p.24)] (interpretation key of the International Contact 
Dermatitis Research Group). 
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Table 2. Suspensions and extracts applied to patch test wells 
 
Test material or 
species Patch series type Strain Source 
Cyanotoxin 
(concentration in 
0.25% w/v lyophilised 
cyanobacteria patch 
preparation) 
Sodium dodecyl 
sulfate (SDS, aka 
sodium lauryl sulfate) 
Positive irritant 
control  Sigma-Aldrich P/L  
Cylindrospermopsis 
raciborskii 
Cyanobacterial cell 
suspension 
AWT 205 
Non-axenic 
Australian Water Technologies culture collection 
Sydney, Australia 
Cylindrospermopsin 
(2.0mg/L) 
C. raciborskii Cyanobacterial LPS extract 
AWT 205 
Non-axenic 
Australian Water Technologies culture collection 
Sydney, Australia  
Microcystis 
aeruginosa 
C. raciborskii 
Aphanizomenon sp. 
 
Cyanobacterial cell 
suspension  
Field sample, North Pine Dam (South-east 
Queensland, Australia) 
Microcystins (200µg/L  
total microcystins 
expressed as MC-LR); 
cylindrospermopsin 
(6.4µg/L) 
M. aeruginosa Cyanobacterial cell suspension  
Field sample, Lake Coolmunda (Southern 
Queensland, Australia) 
Non-toxic (nil detect for 
microcystins) 
M. aeruginosa Cyanobacterial LPS extract  
Field sample, Lake Coolmunda (Southern 
Queensland, Australia)  
M. aeruginosa Cyanobacterial cell suspension 
QH/NR/Ma/03 
Non-axenic 
Queensland Health Scientific Services culture 
collection, Brisbane, Australia 
Microcystins 
[predominantly 
microcystin-LR] (1.60mg/L 
total microcystins 
expressed as MC-LR) 
Anabaena circinalis Cyanobacterial cell suspension  
Field sample, Lake Coolmunda (Southern 
Queensland, Australia) 
Saxitoxins (19µg/L total 
saxitoxins expressed as 
saxitoxin) 
Planktothrix sp. Cyanobacterial cell suspension 
QH/NR/Px/01 
Non-axenic 
Queensland Health Scientific Services culture 
collection, Brisbane, Australia 
Non-toxic (nil detect for 
microcystins) 
Chlorella vulgaris Green algal cell suspension 
CS-42 
Non-axenic 
CSIRO collection of living microalgae, Hobart, 
Australia  
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Table 3. Summary of questionnaire responses: history of cutaneous and 
allergic illness. n (%) 
Outpatients Reference subjects   
Yes No Not sure Yes No 
Not 
sure p 
Eczema or dermatitis  
Ever 
diagnosed 12(60) 4(20) 1(5) 7(37) 12(63) 0 0.04 
Last two 
years 11(55) 3(15) 3(15) 5(26) 13(68) 0 0.01 
 
Asthma  
Ever 
diagnosed 6(30) 13(65) 0 8(42) 10(53) 0 0.51 
Last two 
years 5(25) 14(70) 0 5(26) 13(68) 0 1.0 
 
Hay fever  
Ever 
diagnosed 2(10) 15(75) 1(5) 5(26) 14(74) 0 0.41 
Last two 
years 3(15) 14(70) 1(5) 4(21) 15(79) 0 1.0 
 
Urticaria  
Ever 
diagnosed 1(5) 17(85) 1(5) 2(11) 16(84) 0 1.0 
Last two 
years 0 17(85) 1(5) 1(5) 16(84) 1(5) 1.0 
 
Rash of unknown cause  
Last two 
years 10(50) 4(20) 3(15) 3(16) 15(79) 0 0.003 
  
Rash after 
freshwater 
recreation 
1(5) 16(80) 1(5) 
 
0 15(79) 3(16) 1.0 
 
n=20 for the outpatient subject group; n=19 for the reference group. Where sum of row answers (yes/no/not 
sure) is below the total, shortfall represents unanswered questions. 
 
p-values: Fisher’s exact test comparing proportion of  “yes” and “no” answers between outpatient and 
reference subject groups
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Table 4. Cyanobacterial and algal patch series: positive and equivocal patch test results 
 
 Subject 
Test material Concentration PT01 PTO2  PT04 PT06 PT19 CO05 CO06 CO08 CO09 
C. raciborskii AWT 
205 cell suspension 
0.005%
0.05%
0.25% 
    (++)* (+)** 
(++)* (+)** 
(++)* (+)** 
    
C. raciborskii AWT 
205 LPS extract 
630ppb
6ppm
31ppm 
      (  +/-)*   
North Pine Dam cell 
suspension 
0.005%
0.05%
0.25% 
    (+)*   (+)** 
(++)* (+)** 
(+)*   (+)** 
    
M. aeruginosa Lake 
Coolmunda cell 
suspension 
0.005%
0.05%
0.25% 
    
 
(+/-)* 
         (+)** 
         (+)** 
        (+/-)** 
    
M. aeruginosa Lake 
Coolmunda LPS 
extract 
260ppb
3ppm
13ppm  
    
 
(+/-)* 
  (+/-)*  
(+/-)* 
 
     (+/-)** 
     (+/-)** 
M. aeruginosa 
QH/NR/Ma/03 cell 
suspension  
0.005%
0.05%
0.25% 
  
 
(+/-)* 
  
 
(+/-)* 
 (+/-)*    
A. circinalis cell 
suspension 
0.005%
0.05%
0.25% 
 
(+/- IR)* 
(+ IR)* 
   
(+/-)*  
    
Planktothrix sp. cell 
suspension  
0.005%
0.05%
0.25% 
 
(+)* 
    
(+)* (+)** 
        (+)** 
    
C. vulgaris cell 
suspension  
0.005%
0.05%
0.25% 
(+/- IR)*  (+/-)* 
(+/-)* 
(+/-)* 
 (+)* 
(+)* 
(+)* 
 
(+/-)* 
   
 
   *: grading at 48-hour inspection 
**: grading at 96-hour inspection 
 
Subject prefix “PT” = dermatology outpatient subject 
Subject prefix “CO” = non-patient volunteer 
 Table 5.  Estimated doses of cyanotoxins by the cutaneous route 
 
Cyanotoxin Dose per subject Dose by weight Mouse LD50 (i.p.) 
Cylindrospermopsin 160ng 2.4ng/kg 2.1mg/kg (24 hours); 200µg/kg (5-6 days) [34]
Microcystins 170ng 2.6ng/kg 45-70µg/kg (most toxic forms) [35 (p.140)] 
Saxitoxins 3.8ng 58pg/kg 10-30µg/kg [35 (p.140)] 
 
Dose by weight estimated for a 65kg individual 
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